Labs / ADME, DMPK & toxicology

Avacta Therapeutics
London, United Kingdom · avacta.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Avacta Therapeutics is a clinical stage biopharmaceutical company developing tumor-activated oncology delivery platforms. It develops pre|CISION® peptide drug conjugates to deliver existing cancer therapeutics more selectively to tumors, with operations in London, United Kingdom.
They take quote requests by email.
What they offer
pre|CISION® tumor-activated oncology delivery platform
Develops a peptide drug conjugate platform that masks a toxic payload until it is selectively released by fibroblast activation protein (FAP) in the tumor microenvironment.
Faridoxorubicin (AVA6000) clinical development
Develops a Gen One pre|CISION® peptide drug conjugate form of doxorubicin that has completed Phase 1a testing and is in Phase 1b expansion cohorts.
FAP-Exd (AVA6103) clinical development
Develops a Gen Two pre|CISION® sustained-release version of exatecan that is in Phase 1 testing in multiple disease settings.
What they work on
- Modalities
- Antibody, ADC, Peptide
- Therapeutic areas
- oncology, cancer
- Sites
- London, United Kingdom
- Address
- 58 Wood Lane London W12 7RZ
Similar labs. Aurigene Pharmaceutical Services, Glykos, Manhattan BioSolutions, Oncodesign Services
Found in a contract services directory. Listing built from avacta.com. Work here? Claim this listing.